The findings suggest that the biomarkers Lp‐PLA2 and CTRP‐3 are dysregulated in patients with T2DM who develop CVD and that each biomarker is independently associated with the occurrence of CVD. This evidence concerns the gene C1QTNF3 and type 2 diabetes mellitus.